How effective is SPRAVATO® treatment?
In clinical studies, patients who achieved stable remission with SPRAVATO® augmented with an antidepressant showed a 51% decrease in risk of relapse*. In addition, there was a 70% risk reduction for depressive symptoms among those who achieved a stable response compared to an antidepressant alone.
For individuals with TRD
In clinical studies, improvement of depressive symptoms was demonstrated at four weeks by SPRAVATO® plus an oral antidepressant, compared with placebo nasal spray plus an oral antidepressant. Not all patients will respond to SPRAVATO®.
For individuals with MDSI
In clinical studies, those who took SPRAVATO® and an oral antidepressant experienced a greater reduction of depressive symptoms at 24 hours compared to those who took a placebo plus an oral antidepressant. Further reductions were seen consistently through four weeks (25 days) of treatment, so it is essential to follow the treatment plan that you and your healthcare provider have made. Not all patients will respond to SPRAVATO®.
*As of February 2025, the FDA has approved Spravato as monotherapy for adults living with treatment-resistant depression (TRD).
